newwin
Luciann Nguyen
Settings
← Accounts
biotech

Pierre Fabre Medicament

37
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Pierre Fabre Medicament

New trial — A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

New trialNCT04554914
37/100
Opportunity
Commercial fit0/25
Clinical timing20/20
Biomarker need0/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 2 trial NCT04554914 posted by Pierre Fabre Medicament: "A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases". New trial on a phase 2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 39 days ago.

ConfidenceHigh · 80%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT04554914
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
phase 2
—